Program
CDK2 Inhibitor AVZO-021
Its studies are mostly in Carcinoma, Ovarian Epithelial · Breast Neoplasms, led by Avenzo Therapeutics.
Furthest: phase 2, since Apr 13, 20232 company-led studies, 2 open or runningNext primary completion: Jan 31, 2028 (phase 2)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Avenzo Therapeutics | 22 open or running | phase 2since Apr 13, 2023 | Apr 13, 2023 | Jan 31, 2028phase 2 · NCT05867251 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Apr 13, 2023First study: phase 2 study in Carcinoma, Ovarian EpithelialFirst studyNCT05867251 · 430 planned · United States, Australia
- May 22, 2025Phase 2 study in HR+/HER2- Breast CancerNCT06998407 · 380 planned · United States
Ahead
- Jan 31, 2028Primary completion: phase 2 study in Carcinoma, Ovarian EpithelialNCT05867251
- Aug 2028Primary completion: phase 2 study in HR+/HER2- Breast CancerNCT06998407
TargetBeta
CDK2 →read by rule
“An orally bioavailable inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule
Other programs on CDK2
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| culmerciclib | Sino Biopharmaceutical | phase 3 | 11 |
| CDK2 Inhibitor INCB123667rule | Incyte | phase 3 | 7 |
| tegtociclib | Pfizer | phase 2 | 4 |
| vustanaciclib | regor-pharmaceuticals-inc | phase 2 | 3 |
| CDK2 Inhibitor ECI830 | Novartis | phase 2 | 1 |
| CDK2 Degrader BG-75098rule | BeOne Medicines | phase 1 | 1 |
| CG-7321rule | chengdu-cynogen-bio-pharmaceutical-tech-co-ltd | phase 1 | 1 |
| nkt5097 cdk2rule | nikang-therapeutics-inc | phase 1 | 1 |
| ZE94-0605rule | eilean-therapeutics | phase 1 | 1 |
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06998407HR+/HER2- Breast Cancer · United States | 2 | Recruiting | Aug 2028 | 380 |
| NCT05867251Carcinoma, Ovarian Epithelial · United States, Australia | 2 | Recruiting | Jan 31, 2028 | 430 |
How it is read
Names in the registry
- “AVZO-021”, 2 entries
Conditions, from the studies’ own filings
- Carcinoma, Ovarian Epithelial, 1 study
- Breast Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.